RxDoctor Payments Data

Soudabeh Ahadi, MD

Obstetrics & Gynecology · Monroe, MINPI 1174510275

Payments from drug & device makers

$4,750in general payments, 2019–2025

Across 212 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$778
  • Novo Nordisk$498
  • Astellas Pharma US Inc$472
  • Amgen$423
  • Aspira Women's Health Inc$333
  • Daiichi Sankyo Inc.$305
  • plus $2K from 32 others

What the payments were for

  • Consulting fees$160%
  • Food & beverage$4,47094%
  • Education$2636%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,750 in reported general payments places this provider in the 90th percentile of 1,474 obstetrics & gynecology providers in Michigan.

See all obstetrics & gynecology providers in Michigan

Medicare billing

Part B allowed, 2024
$103,364
Medicare patients
209
Services billed
955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron21$21,772
Estradiol286$19,755
PremarinEstrogens, Conjugated19$9,110
Estradiol (Twice Weekly)Estradiol19$2,960
DottiEstradiol20$2,542
Raloxifene Hcl17$919
Alendronate Sodium82$709
Ibandronate Sodium16$678
Venlafaxine Hcl ErVenlafaxine Hcl26$566
ProgesteroneProgesterone, Micronized14$481
Oxybutynin Chloride ErOxybutynin Chloride16$458
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst65$385
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip43$325
Clobetasol Propionate23$281
SprintecNorgestimate-Ethinyl Estradiol11$256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$472$21,77221 claims
PfizerPremarin$197$9,11019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,474 obstetrics & gynecology providers in Michigan.

Other obstetrics & gynecology in Monroe

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →